Related Experiment Video
Updated: Jul 8, 2026

06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Mycophenolate mofetil in the treatment of retroperitoneal fibrosis
Fareeha Khalil1, M A Mir, Rocco C Venuto
1Department of Medicine, Erie County Medical Centre, University at Buffalo, Buffalo, NY 14212, USA. fkhalil@buffalo.edu
Clinical Rheumatology
|January 11, 2008
Abstract:
The pathogenesis of idiopathic retroperitoneal fibrosis (IRPF) has been attributed to an autoimmune response to atherosclerotic lipid material leaking from blood vessels. Corticosteroids and cytotoxic agents have been used for therapy. Based on the immunosuppressive and anti-fibrotic action of mycophenolate, we administered this agent to a patient with biopsy-proven IRPF and achieved a rapid, complete and sustained remission with a 6-year follow-up.